L
Laura Cicconi
Researcher at University of Rome Tor Vergata
Publications - 53
Citations - 2598
Laura Cicconi is an academic researcher from University of Rome Tor Vergata. The author has contributed to research in topics: Acute promyelocytic leukemia & Myeloid leukemia. The author has an hindex of 17, co-authored 51 publications receiving 2120 citations. Previous affiliations of Laura Cicconi include Yahoo!.
Papers
More filters
Journal ArticleDOI
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
Francesco Lo-Coco,Giuseppe Avvisati,Marco Vignetti,Christian Thiede,Simona Iacobelli,Felicetto Ferrara,Paola Fazi,Laura Cicconi,E. Di Bona,Giorgina Specchia,Simona Sica,Mariadomenica Divona,Alessandro Levis,Walter Fiedler,Elisa Cerqui,Massimo Breccia,Giuseppe Fioritoni,Mario Cazzola,L. Melillo,Enrica Morra,Bernd Hertenstein,Mohammed Wattad,Michael Lübbert,Mathias Hänel,Norbert Schmitz,Alessandro Rambaldi,G. La Nasa,Mario Luppi,Fabio Ciceri,Olimpia Finizio,Adriano Venditti,Francesco Fabbiano,Konstanze Döhner,M. Sauer,Arnold Ganser,Sergio Amadori,Franco Mandelli,Hartmut Döhner,Gerhard Ehninger +38 more
TL;DR: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.
Journal ArticleDOI
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Uwe Platzbecker,Giuseppe Avvisati,Laura Cicconi,Christian Thiede,Francesca Paoloni,Marco Vignetti,Felicetto Ferrara,Mariadomenica Divona,Francesco Albano,Fabio Efficace,Paola Fazi,Marco Sborgia,Eros Di Bona,Massimo Breccia,Erika Borlenghi,Roberto Cairoli,Alessandro Rambaldi,Lorella Melillo,Giorgio La Nasa,Walter Fiedler,Peter Brossart,Bernd Hertenstein,Helmut R. Salih,Mohammed Wattad,Michael Lübbert,Christian Brandts,Mathias Hänel,Christoph Röllig,Norbert Schmitz,Hartmut Link,Chiara Frairia,Enrico Maria Pogliani,Claudio Fozza,Alfonso Maria D'Arco,Nicola Di Renzo,Agostino Cortelezzi,Francesco Fabbiano,Konstanze Döhner,Arnold Ganser,Hartmut Döhner,Sergio Amadori,Franco Mandelli,Gerhard Ehninger,Richard F. Schlenk,Francesco Lo-Coco +44 more
TL;DR: The results show that the advantages of ATRA-ATO over ATra-CHT increase over time and that there is significantly greater and more sustained antileukemic efficacy of ATO-ATRA compared with ATRA -CHT in low- and intermediate-risk APL.
Journal ArticleDOI
Retinoic acid receptors: from molecular mechanisms to cancer therapy.
Alessandra di Masi,Loris Leboffe,Elisabetta De Marinis,Francesca Pagano,Laura Cicconi,Cécile Rochette-Egly,Francesco Lo-Coco,Paolo Ascenzi,Clara Nervi +8 more
TL;DR: An overview of the biochemical and molecular mechanisms that regulate the RA and retinoid signaling pathways is provided and mechanisms through which deregulation of RA signaling pathways ultimately impact on cancer are examined.
Journal ArticleDOI
Current management of newly diagnosed acute promyelocytic leukemia
Laura Cicconi,Francesco Lo-Coco +1 more
TL;DR: The results of large clinical studies conducted in newly diagnosed APL as well as the recommendations for appropriate diagnosis, prevention and management of the main complications associated with modern treatment of the disease are reviewed.
Journal ArticleDOI
PML–RARα kinetics and impact of FLT3 –ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy
Laura Cicconi,Mariadomenica Divona,Claudia Ciardi,Tiziana Ottone,A Ferrantini,Serena Lavorgna,Valentina Alfonso,Francesca Paoloni,Alfonso Piciocchi,Giuseppe Avvisati,Felicetto Ferrara,E. Di Bona,Francesco Albano,Massimo Breccia,Elisa Cerqui,Marco Sborgia,Mariagrazia Kropp,Armando Santoro,Alessandro Levis,Simona Sica,Sergio Amadori,Maria Teresa Voso,Franco Mandelli,Francesco Lo-Coco +23 more
TL;DR: It is shown at the molecular level that ATRA–ATO exerts at least equal and probably superior antileukaemic efficacy compared with ATRA-CHT in low–intermediaterisk APL and may abrogate the negative prognostic impact of FLT3–ITD.